000300752 001__ 300752
000300752 005__ 20250503112950.0
000300752 0247_ $$2doi$$a10.3389/fimmu.2025.1575509
000300752 0247_ $$2pmid$$apmid:40313957
000300752 0247_ $$2pmc$$apmc:PMC12043573
000300752 037__ $$aDKFZ-2025-00912
000300752 041__ $$aEnglish
000300752 082__ $$a610
000300752 1001_ $$0P:(DE-He78)75b4f74b753faeb8e48695b4710b3612$$aJordan, Melanie$$b0$$eFirst author$$udkfz
000300752 245__ $$aDendritic cells in multiple myeloma: from immune evasion to therapeutic potential.
000300752 260__ $$aLausanne$$bFrontiers Media$$c2025
000300752 3367_ $$2DRIVER$$aarticle
000300752 3367_ $$2DataCite$$aOutput Types/Journal article
000300752 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746194743_32$$xReview Article
000300752 3367_ $$2BibTeX$$aARTICLE
000300752 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300752 3367_ $$00$$2EndNote$$aJournal Article
000300752 500__ $$a#EA:D431#LA:D431#
000300752 520__ $$aMultiple myeloma (MM) is a type of hematologic cancer characterized by the uncontrolled clonal expansion of plasma cells in the bone marrow (BM). This leads to significant dysfunction and suppression of the immune system in affected patients. Myeloma cells employ sophisticated strategies to manipulate immune and non-immune cells, evading immune surveillance and enhancing their survival. One key factor in this evasion is the disruption of dendritic cell (DC)-mediated immune mechanisms. Extensive evidence indicates that in the presence of myeloma cells, DC numbers are notably reduced, and their phenotype and function are altered, impairing their ability to present antigens and activate robust T-cell responses effectively. Despite rapid advances in MM treatment, with promising strategies such as DC-based vaccines being already achieved, DC dysfunction remains a substantial hurdle, associated with or contributing to poor therapeutic outcomes, disease relapse, and MM's persistence as an incurable disease. To address these challenges, it is essential to understand the intricate mechanisms through which myeloma cells transform DCs into their 'accomplices,' undermining immune responses. This review comprehensively summarizes the current understanding of the role of DCs in MM. Additionally, it evaluates the potential of DCs in anti-MM immunotherapy, discussing persistent challenges and highlighting emerging perspectives that may lead to promising breakthroughs for improved patient outcomes.
000300752 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000300752 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300752 650_7 $$2Other$$aDC vaccine therapy
000300752 650_7 $$2Other$$adendritic cells
000300752 650_7 $$2Other$$aimmune evasion
000300752 650_7 $$2Other$$amultiple myeloma
000300752 650_7 $$2Other$$atumor microenvironment
000300752 7001_ $$0P:(DE-He78)da4a4bbbdbe57436d712dd4130f6cd4d$$aMorschl, Johannes$$b1$$udkfz
000300752 7001_ $$0P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aAutenrieth, Stella$$b2$$eLast author$$udkfz
000300752 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2025.1575509$$gVol. 16, p. 1575509$$p1575509$$tFrontiers in immunology$$v16$$x1664-3224$$y2025
000300752 909CO $$ooai:inrepo02.dkfz.de:300752$$pVDB
000300752 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4f74b753faeb8e48695b4710b3612$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300752 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da4a4bbbdbe57436d712dd4130f6cd4d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300752 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300752 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000300752 9141_ $$y2025
000300752 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000300752 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000300752 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000300752 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-12-29T15:23:07Z
000300752 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000300752 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000300752 9202_ $$0I:(DE-He78)D431-20160331$$kD431$$lDentritische Zellen bei Infektionen und Krebs$$x0
000300752 9201_ $$0I:(DE-He78)D431-20160331$$kD431$$lDentritische Zellen bei Infektionen und Krebs$$x0
000300752 9200_ $$0I:(DE-He78)D431-20160331$$kD431$$lDentritische Zellen bei Infektionen und Krebs$$x0
000300752 980__ $$ajournal
000300752 980__ $$aVDB
000300752 980__ $$aI:(DE-He78)D431-20160331
000300752 980__ $$aUNRESTRICTED